LeonaBio (LONA) Cash from Financing Activities (2019 - 2025)
LeonaBio (LONA) posted quarterly Cash from Financing Activities of $82.4 million for Q4 2025, up 242361.76% year-over-year from N/an in Q4 2024, and up 242361.76% quarter-over-quarter from $34000.0 in Q4 2024.
LeonaBio (LONA) Cash from Financing Activities (2019 - 2025) Analysis & Trends
LeonaBio (LONA) has reported Cash from Financing Activities for 7 consecutive years, with $82.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 242361.76% year-over-year to $82.4 million; the TTM figure through Dec 2025 stood at $82.5 million (up 41558.08% YoY), while the FY2025 annual figure was $82.5 million, up 42405.67% from the prior year.
- Cash from Financing Activities advanced to $82.4 million in Q4 2025 per LONA's latest filing, from $34000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.2 million in Q1 2021 and bottomed at -$260000.0 in Q2 2021.
- Historically, Cash from Financing Activities has averaged $13.9 million across 5 years, with a median of $147000.0 in 2022.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities sank 100.3% — and 2025, when it soared 242361.76%.
- LeonaBio's Cash from Financing Activities stood at $13000.0 in 2021, then jumped by 1030.77% to $147000.0 in 2022, then grew by 3.4% to $152000.0 in 2023, then plunged by 77.63% to $34000.0 in 2024, then jumped by 242361.76% to $82.4 million in 2025.
- Business Quant data shows LONA's Cash from Financing Activities at $82.4 million in Q4 2025, $34000.0 in Q4 2024, and $12000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 82.44 Mn |
| Dec 31, 2025 | 82.44 Mn |
| Dec 31, 2024 | 34,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Dec 31, 2023 | 152,000.00 |
| Dec 31, 2023 | 152,000.00 |
| Jun 30, 2023 | 242,000.00 |
| Jun 30, 2023 | 242,000.00 |
| Mar 31, 2023 | 99,000.00 |
| Mar 31, 2023 | 99,000.00 |
| Dec 31, 2022 | 147,000.00 |
| Dec 31, 2022 | 147,000.00 |
| Jun 30, 2022 | 297,000.00 |
| Jun 30, 2022 | 297,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Dec 31, 2021 | 13,000.00 |
| Dec 31, 2021 | 13,000.00 |